G architects’ Post

Today is the day! Tune in to our latest webinar featuring the Wheeler Bio, Inc. team and a panel of distinguished CMC consultants including Libby Russell, PhD, Ali Siahpush, PhD, and Stephen Monks at 1PM ET to hear a nuanced and honest discussion on the relationship between consultants and CDMOs, common pain points, and how priorities can be aligned in favor of client success. Every attendee will also gain access to an exclusive investor survey report full of valuable insights for early-stage biotechs! Register now to claim your spot and learn more about this important topic. #Webinar #CMC #Biologics #Pharma #Biotech

This morning, Lonza reported its Half-Year 2024 results. In Biologics, we delivered continued robust sales growth of 6.5% (7.3% CER) versus H1 2023, corresponding to mid-teens sales growth when excluding COVID-related mRNA sales in the prior year period. We saw continued strong demand for large-scale in our Mammalian business, and our agreement to acquire the Genentech Vacaville (US) site - which will extend our large-scale offering - is expected to close in Q4 2024. In Bioconjugates, sales were driven by strong commercial demand and interest in our strengthened ADC offering following the Synaffix acquisition.   Read more here: https://lnkd.in/d3ny7zq7   #AHealthierWorld #FinancialResults #Biologics

Headed to AAPS PharmSci360 next week? Our team of experts, Dr Campbell Bunce PhD MBA, Parviz A. Shamlou, Zoe Yi Zhang, Julie Grace and Yang Wang-Smalley, will be there in booth #2711 to discuss your biologic's drug development challenges and share how our fully integrated CDMO+CRO capabilities can help you overcome them faster and with greater success.     Also, make sure not to miss our poster sessions on Monday & Wednesday: -Monday, October 21 at 3:30 PM – ‘Platform Approach for Identifying the Most Functional and Developable Bispecific T Cell Engager’ -Wednesday, October 23 at 12:30 PM – ‘EpiScreen® 2.0 Time Course Assay: A Sensitive and Data Rich Tool for Pre-Clinical Immunogenicity Testing of Biologics’ From our recently enhanced AbZelectPRO cell line development platform, offering quicker doubling times and 8g/L in high-performing titres to our comprehensive immunogenicity assessment platform, EpiScreen 2.0, our team welcomes the opportunity to discuss how our end-to-end design, development and cGMP manufacturing capabilities can help de-risk and streamline your biopharmaceutical program from discovery through to commercial product launch. Click here to schedule a meeting with our team at AAPS: https://lnkd.in/eR29rDSE   #PharmaSci360 #Bioconjugation #DrugDevelopment #CDMO #CRO #Biologics

Last year's #EuroBiosimilars conference was a game-changer for the career. Can't wait for #EuroBiosimilars2025! Who else is excited? Join Euro Biosimilars 2025 for unparalleled #networkingopportunities. Connect with #industryleaders, researchers, and professionals in the #biosimilars field. Build valuable connections and #partnerships. Visit: https://cutt.ly/1wTmjlWf #workshops #biologics #pharmaceuticals #pharmacy #generics #biologicalmedicine #bioinformatics #covid19 #monoclonalantibodies #globaleducation #exhibition #sponsorship #pharma #Pharmaceutical #drugdesign #drugdiscovery #oncology #biopharmaceutics

Moving Medicine Forward If you plan to take your next biologica candiate from bench to patients and plan to attend the upcoming AAPS Event in Salt Lake City, join me and my colleague Campbell Bunce next week for a discussion on how Abzena can help move your medicine forward. Stay healthy and well Abzena

More CDMO Expansion News 📈 SEKISUI Diagnostics has completed its £15.7 Million expansion of its GMP certified microbial manufacturing site. Upon Licensing, clinical-grade enzyme, protein and much more can begin to be produced. The Bioproduction division of SEKISUI Diagnostics will benefit from increased capacity and manufacturing capabilities. Bob Schruender, President and CEO noted “This investment supports our growth in the biologics CDMO market” Congratulations to all involved, incredible to see the expansion happening across the CDMO space. #CDMO #Biologics #CRDMO

The Landscape of Biologics is Evolving Rapidly 💡 The biologics industry is undergoing rapid evolution, with over 80 biologics set to lose exclusivity between 2024 and 2028. Among them are blockbuster products such as Merck’s Keytruda and Regeneron Pharmaceuticals’ Eylea, with a combined global sales of around $25 billion. This wave of exclusivity loss paves the way for biosimilars, intensifying competition in the landscape. By 2028, the global biosimilars market is projected to reach a staggering $67 billion. In this dynamic market, innovator pharma companies are facing challenges in maximizing the value of their biologics, especially in the late lifecycle stage and beyond patent expiry. At Inbeeo, we specialize in navigating these shifts. Our expertise lies in helping clients maximize patient value from their assets, particularly in the lead-up to loss of exclusivity. Reach out to us today to explore how we can assist you in navigating the changing biologics landscape and unlocking the full potential of your asset! #Lifesciences #Innovation #Biologics #Biosimilars #Patientaccess

‼️Next stop #FestivalofBiologics Connect 👇to further discuss how Patheon by Thermo Fisher Scientific can support your large molecule molecule journey

If you are into generative biologics design using Generative Biologics, you can now easily track: 🔍 Which properties were optimized effectively 📊 What percentage of biologics meet your acceptance criteria

🚀 Exciting Update from Our Generative Biologics Platform! We’re thrilled to announce the latest enhancement to our platform – Optimization Insights. This new feature empowers users with a clear, user-friendly view of the optimization history for each model. Now, you can easily track: 🔍 Which properties were optimized effectively 📊 What percentage of biologics meet your acceptance criteria This addition streamlines your workflow, making it easier to analyze and refine your models with greater precision. We’re committed to providing tools that drive innovation and help you accelerate your discoveries in #biologics. Stay tuned for more updates! Visit: https://lnkd.in/dEmWp5fF to stay informed. #GenerativeBiologics #PharmaAI #NewFeatures #BiologicsWorkflow